Skip to main content
Top
Published in: Clinical and Experimental Nephrology 6/2013

Open Access 01-12-2013 | Original Article

Nationwide survey on current treatments for IgA nephropathy in Japan

Authors: Keiichi Matsuzaki, Yusuke Suzuki, Junichiro Nakata, Naoko Sakamoto, Satoshi Horikoshi, Tetsuya Kawamura, Seiichi Matsuo, Yasuhiko Tomino

Published in: Clinical and Experimental Nephrology | Issue 6/2013

Login to get access

Abstract

Background

A wide variety of treatments, including tonsillectomy and steroid pulse therapy (TSP), are performed for the various stages of IgA nephropathy (IgAN) in Japan. However, the current status of treatments for IgAN patients in Japan is still unclear. The objective of the present study was to investigate the current status of treatments for IgAN patients.

Methods

A nationwide survey was conducted in 2008 by sending questionnaires to the 1,194 teaching hospitals of the Japanese Society of Nephrology (JSN) via Progressive Renal Diseases Research, Research on intractable disease, from the Ministry of Health, Labour and Welfare of Japan.

Results

Among the total 376 hospitals (31.4 %) that responded, 188 hospitals (66.2 % in the internal medicine departments) performed TSP, out of which 137 hospitals (61.4 %) had begun to perform TSP in the period from 2004 to 2008. The following two major steroid pulse protocols in TSP were used: (1) three cycles over 3 consecutive weeks and (2) three cycles every 2 months. Approximately 68 % of pediatric hospitals (68 hospitals) performed combination therapy with prednisolone, azathioprine, heparin-warfarin and dipyridamole. The clinical remission rates for hematuria and proteinuria after TSP tended to be higher than those following other corticosteroid therapies. Almost all hospitals prescribed antiplatelet agents and renin angiotensin system inhibitor (RAS-I).

Conclusion

In addition to popular treatments such as antiplatelet agents and RAS-I, TSP is becoming a standard treatment for adult IgAN patients in Japan.
Literature
1.
go back to reference D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;245:709–27. D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;245:709–27.
2.
go back to reference Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 1990;89:209–15.PubMedCrossRef Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 1990;89:209–15.PubMedCrossRef
3.
go back to reference Li L-S, Liu Z-H. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004;66:920–3.PubMedCrossRef Li L-S, Liu Z-H. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004;66:920–3.PubMedCrossRef
4.
go back to reference Simon P, Ramee MP, Boulahrouz R, Stanescu C, Charasse C, Ang KS, et al. Epidemiologic data of primary glomerular diseases in western France. Kidney Int. 2004;66:905–8.PubMedCrossRef Simon P, Ramee MP, Boulahrouz R, Stanescu C, Charasse C, Ang KS, et al. Epidemiologic data of primary glomerular diseases in western France. Kidney Int. 2004;66:905–8.PubMedCrossRef
6.
go back to reference D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004;24:179–96.PubMedCrossRef D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004;24:179–96.PubMedCrossRef
8.
go back to reference Progressive Renal Diseases Research, Research on intractable disease, from the Ministry of Health Labors and Welfare of Japan. Clinical guides for Immunoglobulin A (IgA) nephropathy in Japan, third version. Nihon Jinzo Gakkai shi 2011; 53:123–35. Progressive Renal Diseases Research, Research on intractable disease, from the Ministry of Health Labors and Welfare of Japan. Clinical guides for Immunoglobulin A (IgA) nephropathy in Japan, third version. Nihon Jinzo Gakkai shi 2011; 53:123–35.
9.
go back to reference Kobayashi Y, Fujii K, Hiki Y, Tateno S. Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Q J Med. 1986;61:935–43.PubMed Kobayashi Y, Fujii K, Hiki Y, Tateno S. Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Q J Med. 1986;61:935–43.PubMed
10.
go back to reference Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.PubMedCrossRef Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.PubMedCrossRef
11.
go back to reference Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.PubMedCrossRef Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.PubMedCrossRef
12.
go back to reference Sato M, Hotta O, Tomioka S, Chiba S, Miyazaki M, Noshiro H, et al. Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy. Nephron Clin Pract. 2003;93:c137–45.PubMedCrossRef Sato M, Hotta O, Tomioka S, Chiba S, Miyazaki M, Noshiro H, et al. Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy. Nephron Clin Pract. 2003;93:c137–45.PubMedCrossRef
13.
go back to reference Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.PubMedCrossRefPubMedCentral Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.PubMedCrossRefPubMedCentral
14.
go back to reference Kawaguchi T, Ieiri N, Yamazaki S, Hayashino Y, Gillespie B, Miyazaki M, et al. Clinical effectiveness of steroid pulse therapy combined with tonsillectomy in patients with immunoglobulin A nephropathy presenting glomerular haematuria and minimal proteinuria. Nephrology. 2010;15:116–23.PubMedCrossRef Kawaguchi T, Ieiri N, Yamazaki S, Hayashino Y, Gillespie B, Miyazaki M, et al. Clinical effectiveness of steroid pulse therapy combined with tonsillectomy in patients with immunoglobulin A nephropathy presenting glomerular haematuria and minimal proteinuria. Nephrology. 2010;15:116–23.PubMedCrossRef
15.
go back to reference Miura N, Imai H, Kikuchi S, Hayashi S, Endoh M, Kawamura T, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.PubMedCrossRef Miura N, Imai H, Kikuchi S, Hayashi S, Endoh M, Kawamura T, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.PubMedCrossRef
16.
go back to reference Yoshikawa N, Igarashi T, Ishikura K, Kaku Y, Nakazato H, Kamei K, et al. Guidelines for the treatment of childhood IgA nephropathy. Nihon Jinzo Gakkai shi. 2008;50:31–41.PubMed Yoshikawa N, Igarashi T, Ishikura K, Kaku Y, Nakazato H, Kamei K, et al. Guidelines for the treatment of childhood IgA nephropathy. Nihon Jinzo Gakkai shi. 2008;50:31–41.PubMed
17.
go back to reference Yoshikawa N, Ito H, Sakai T. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol. 1999;10:101–9.PubMed Yoshikawa N, Ito H, Sakai T. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol. 1999;10:101–9.PubMed
18.
go back to reference Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1:511–7.PubMedCrossRef Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1:511–7.PubMedCrossRef
19.
go back to reference Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, et al. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study. Pediatr Nephrol. 2008;23:757–63.PubMedCrossRef Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, et al. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study. Pediatr Nephrol. 2008;23:757–63.PubMedCrossRef
20.
go back to reference Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol. 2010;21:1783–90.PubMedCrossRefPubMedCentral Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol. 2010;21:1783–90.PubMedCrossRefPubMedCentral
21.
go back to reference Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, et al. Long term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol. 2011;6:1301–7.PubMedCrossRefPubMedCentral Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, et al. Long term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol. 2011;6:1301–7.PubMedCrossRefPubMedCentral
22.
go back to reference Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton). 2004;9:177–85.CrossRef Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton). 2004;9:177–85.CrossRef
23.
go back to reference Barratt J, Feehally J, Lai KN (ed): Recent Advances in IgA Nephropathy. 1st ed. World Scientific Pub Co Inc; 2009: Chapter 24 “Other non-immunomodulatory agents”. Barratt J, Feehally J, Lai KN (ed): Recent Advances in IgA Nephropathy. 1st ed. World Scientific Pub Co Inc; 2009: Chapter 24 “Other non-immunomodulatory agents”.
24.
go back to reference Chan MK, Kwan SY, Chan KW, Yeung CK. Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. Am J Kidney Dis. 1987;9:417–21.PubMed Chan MK, Kwan SY, Chan KW, Yeung CK. Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. Am J Kidney Dis. 1987;9:417–21.PubMed
25.
go back to reference Lee GS, Choong HL, Chiang GSC, Woo KT. Three year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology (Carlton). 1997;3:117–21.CrossRef Lee GS, Choong HL, Chiang GSC, Woo KT. Three year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology (Carlton). 1997;3:117–21.CrossRef
26.
go back to reference Tomino Y. Long term effects of dilazep hydrochloride, an anti-platelet drug, on patients with IgA nephropathy—reports of 5-year treatment. Curr. Top. Pharmacol. 2007;11:45–9. Tomino Y. Long term effects of dilazep hydrochloride, an anti-platelet drug, on patients with IgA nephropathy—reports of 5-year treatment. Curr. Top. Pharmacol. 2007;11:45–9.
27.
go back to reference Taji Y, Kuwahara T, Shikata S, Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol. 2006;10:268–73.PubMedCrossRef Taji Y, Kuwahara T, Shikata S, Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol. 2006;10:268–73.PubMedCrossRef
28.
29.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:139–274. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:139–274.
30.
go back to reference Suzuki Y, Thang NT, Horikoshi S, Shirato I, Nakamura S, Kimura M, et al. Effect of valsartan, an angiotensin II AT 1 receptor blocker, on the glomerular fibrosis of IgA nephropathy in ddY mice. Nephron. 2000;86:374–5.PubMedCrossRef Suzuki Y, Thang NT, Horikoshi S, Shirato I, Nakamura S, Kimura M, et al. Effect of valsartan, an angiotensin II AT 1 receptor blocker, on the glomerular fibrosis of IgA nephropathy in ddY mice. Nephron. 2000;86:374–5.PubMedCrossRef
31.
go back to reference Li PK-T, Leung CB, Chow KM, Cheng YL, Fung SK-S, Mak SK, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751–60.PubMedCrossRef Li PK-T, Leung CB, Chow KM, Cheng YL, Fung SK-S, Mak SK, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751–60.PubMedCrossRef
32.
go back to reference Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18:1880–8.PubMedCrossRef Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18:1880–8.PubMedCrossRef
33.
go back to reference Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE Inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578–83.PubMedCrossRef Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE Inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578–83.PubMedCrossRef
34.
go back to reference Tomino Y, Kawamura T, Kimura K, Endoh M, Hosoya T, Horikoshi S, et al. Antiproteinuric effect of olmesartan in patients with IgA nephropathy. J Nephrol. 2009;2:224–31. Tomino Y, Kawamura T, Kimura K, Endoh M, Hosoya T, Horikoshi S, et al. Antiproteinuric effect of olmesartan in patients with IgA nephropathy. J Nephrol. 2009;2:224–31.
35.
go back to reference Moriyama T, Amamiya N, Ochi A, Tsuruta Y, Shimizu A, Kojima C, et al. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function. Clin Exp Nephrol. 2011;15:700–7.PubMedCrossRef Moriyama T, Amamiya N, Ochi A, Tsuruta Y, Shimizu A, Kojima C, et al. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function. Clin Exp Nephrol. 2011;15:700–7.PubMedCrossRef
36.
go back to reference Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18–25.PubMedCrossRef Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18–25.PubMedCrossRef
Metadata
Title
Nationwide survey on current treatments for IgA nephropathy in Japan
Authors
Keiichi Matsuzaki
Yusuke Suzuki
Junichiro Nakata
Naoko Sakamoto
Satoshi Horikoshi
Tetsuya Kawamura
Seiichi Matsuo
Yasuhiko Tomino
Publication date
01-12-2013
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 6/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0779-7

Other articles of this Issue 6/2013

Clinical and Experimental Nephrology 6/2013 Go to the issue

Images in Nephrology

Polycystic horseshoe kidney

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.